A great occasion to get to know more on three Alzheimer’s Disease IMI (Innovative Medicines Initiative) projects, was at the 27th Alzheimer Europe Conference (#27AEC), held in Berlin from 2-4 October. At a symposium convened by Eli Lilly, entitled: “Engaging with patient organisations within IMI consortia to inform quality, relevance and value in Alzheimer’s research…
In September 2017, two articles about the EPAD project appeared in the media. On 19 September, the Italian newspaper “la Repubblica” published an article entitled “L’Alzheimer si combatte giocando d’anticipo” including an interview and quotes from Prof. Giovanni Frisoni from the University of Geneva. He highlighted the EPAD project and described it as “il piu…
The EPAD project regrets to announce the departure of Lennert Steukers. Lennert worked full time as project manager for Janssen on the IMI-EPAD project and provided the overall management to the project. In this role, he notably supported the coordinator, executive committee and the WP leaders in day-to-day management. He was also involved in EPAD’s…
On 7 September, the European Federation of Pharmaceutical Industries and Associations (EFPIA) held an event under the banner “Unlocking tomorrow’s cures” in Brussels, Belgium. The EFPIA Rentrée 2017 gathered six scientists working on groundbreaking, innovative and life-changing therapies: Dr Frank Bähner, Area Head Prophylactic Vaccines at Curevac, explained the advantages of mRNA vaccines where pandemics…
On 31 July, The Times Scotland published an article entitled: “Everyday pill to stop dementia in its tracks is tested in Scotland” where the EPAD project was featured. In this great article wrote by Helen Puttick, the health reporter for The Times in Scotland, Prof Craig Ritchie, EPAD co-coordinator, explained dementia prevention and mentioned that…
What is your current role in EPAD? I am a biostatistician and therefore my key role is in the statistical work package (WP2). I have mostly been involved in writing the protocol for the proof-of-concept study, which has been evolving since I joined EPAD in February 2016. WP2 is also responsible for statistical modelling of…
What is your current role in EPAD? I work as a clinical project manager in the Gérontopôle team at Toulouse University Hospital coordinated by Pr Bruno Vellas who is the EPAD National Lead for France. I was designated to be the national study coordinator for EPAD project in 2015. We are involved in two major…
The European Prevention of Alzheimer’s Dementia Consortium (EPAD) seeks a Global Trial Leader. There have been no new treatments for Alzheimer’s Dementia for over 15 years and there are no interventions on the market at all for disease modification or prevention. EPAD is the world’s largest ever dedicated platform for testing new interventions to prevent…
EPAD is establishing a Europe-wide cohort of over 6,000 participants, of which 1,500 will be invited to participate in a trial to test new treatments for prevention of Alzheimer’s dementia. The EPAD Longitudinal Cohort Study (EPAD-LCS) opened for recruitment in May 2016. It is a core part of the EPAD project that links participants in…
The European Prevention of Alzheimer’s Dementia (EPAD) project launched its second video about amyloid. This animation movie tries to explain what we currently understand about amyloid and how it relates to dementia. EPAD Research Participants may be invited to take part in a clinical trial if test results suggest abnormal levels of a protein called…
